Cell fusion as a link between the SARS-CoV-2 spike protein, COVID-19 complications, and vaccine side effects

Yuri Lazebnik

doi:10.18632/oncotarget.28088

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Cell fusion as a link between the SARS-CoV-2 spike protein, COVID-19 complications, and vaccine side effects

Yuri Lazebnik _

PDF | Full Text | How to cite | Press Release

Oncotarget. 2021; 12:2476-2488. https://doi.org/10.18632/oncotarget.28088

Metrics: PDF 2230 views | Full Text 23998 views | ?

Abstract

Yuri Lazebnik1

1 Lerna Consulting, New Haven, CT 06511, USA

Correspondence to:

Yuri Lazebnik,

email:

[email protected]

Keywords: cell fusion; thrombosis; neuropathy; cancer; vaccines

Received: September 07, 2021 Accepted: September 24, 2021 Published: December 07, 2021

Copyright: © 2021 Lazebnik. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

A distinctive feature of the SARS-CoV-2 spike protein is its ability to efficiently fuse cells, thus producing syncytia found in COVID-19 patients. This commentary proposes how this ability enables spike to cause COVID-19 complications as well as side effects of COVID-19 vaccines, and suggests how these effects can be prevented.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28088

Publication Alerts

AARC Annual Meeting 2025

Post-Publication Promotion

Research Perspectives:

Cell fusion as a link between the SARS-CoV-2 spike protein, COVID-19 complications, and vaccine side effects

Abstract

Publication Alerts

Oncoscience

AARC Annual Meeting 2025

Post-Publication Promotion

Research Perspectives:

Cell fusion as a link between the SARS-CoV-2 spike protein, COVID-19 complications, and vaccine side effects

Abstract